Actelion CEO against large shareholder

* Actelion subbject of sustained takeover talk

* Wants to stay independent

ALLSCHWIL, Dec 10 (BestGrowthStock) – The chief executive of
Actelion Ltd (ATLN.VX: ) said on Friday he is against a large
shareholder that could influence the future of Europe’s largest
biotech company, for weeks subject to intense takeover talk.

“We don’t want … any type of shareholding that blocks the
company,” Jean-Paul Clozel said on the fringes of the
inauguration of the company’s new headquarters in Allschwil,
near Basel.

Actelion was open to partnerships and cooperation with other
companies, but intended to stay independent, Clozel said.

Actelion has been the subject of sustained takeover
speculation, driving its share price higher.

Clozel, the ex-Roche (ROG.VX: ) scientist who founded Actelion
(ATLN.VX: ) in 1997, is digging in to defend the Swiss biotech
company in a battle that could mirror the fight for control of
Genzyme (GENZ.O: ). [ID:nLDE6AI1ES]

Global biotech market leader Amgen(AMGN.O: ) has been mooted
as a potential suitor fro Actelion, as have drugmakers
Bristol-Myers Squibb(BMY.N: ), GlaxoSmithKline(GSK.L: ) und
Novartis(NOVN.VX: ).
(Reporting by Paul Arnold; Writing by Jason Rhodes; Editing by
Hans Peters)

Actelion CEO against large shareholder